Second-generation tricyclic pyrimido-pyrrolo-oxazine mTOR inhibitor with predicted blood-brain barrier permeability.

Borsari, Chiara; Keles, Erhan; Treyer, Andrea; De Pascale, Martina; Hebeisen, Paul; Hamburger, Matthias; Wymann, Matthias P

Borsari, Chiara; Keles, Erhan; Treyer, Andrea; De Pascale, Martina; Hebeisen, Paul; Hamburger, Matthias; Wymann, Matthias P.

Afiliação

Borsari C; Department of Biomedicine, University of Basel Mattenstrasse 28 4058 Basel Switzerland Matthias.Wymann@Unibas.ch.
Keles E; Department of Biomedicine, University of Basel Mattenstrasse 28 4058 Basel Switzerland Matthias.Wymann@Unibas.ch.
Treyer A; Pharmaceutical Biology, Pharmacenter, University of Basel Klingelbergstrasse 50 4056 Basel Switzerland.
De Pascale M; Department of Biomedicine, University of Basel Mattenstrasse 28 4058 Basel Switzerland Matthias.Wymann@Unibas.ch.
Hebeisen P; Department of Biomedicine, University of Basel Mattenstrasse 28 4058 Basel Switzerland Matthias.Wymann@Unibas.ch.
Hamburger M; PIQUR Therapeutics AG Hochbergerstrasse 60 4057 Basel Switzerland.
Wymann MP; Pharmaceutical Biology, Pharmacenter, University of Basel Klingelbergstrasse 50 4056 Basel Switzerland.

RSC Med Chem ; 12(4): 579-583, 2021 Jan 12.

Article em En | MEDLINE | ID: mdl-34041490

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies / Risk_factors_studies Idioma: En Revista: RSC Med Chem Ano de publicação: 2021 Tipo de documento: Article País de publicação: Reino Unido

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google